Nasal spray shows promise for tough asthma in early trial
NCT ID NCT05985694
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested an experimental nasal spray called AD17002 in 40 adults with poorly controlled moderate-to-severe eosinophilic asthma. Participants self-administered the spray twice a week for six weeks. The goal was to see if it could improve lung function and reduce the need for rescue inhalers, while also checking safety and ease of use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AD17002 (a nasal spray immunomodulator)
- What this could lead to
- If it works, this could point toward a new way to control moderate-to-severe eosinophilic asthma without relying solely on standard inhalers.
- What could go wrong
- This is an early-phase trial with only 40 people, so results may not apply widely. The treatment may not improve lung function or symptoms, and side effects from the nasal spray are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart inhalers track Fasenra's asthma control over full dosing cycle
- Blood cell study may personalize asthma and sinusitis treatment
- Asthma Drug's gene secrets revealed in small study
- Proteomics may unlock key clues to mepolizumab success in rare lung disease
- New asthma pill shows promise in Mid-Stage trial
- Nasal spray could tame tough asthma Flare-Ups